Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus
Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ
Published in Metabolism
Methodology
Dose-ranging placebo-controlled study of vanadyl sulfate (75-300 mg/day) for six weeks in adults with type 2 diabetes, with clamp and gene-expression endpoints.
Key Findings
Only the higher dose produced modest reductions in fasting glucose and HbA1c; insulin sensitivity improvements were inconsistent and gastrointestinal effects were dose limiting.
Conclusions
Vanadyl sulfate produces limited, dose-dependent glycaemic effects with a narrow tolerability window.
Limitations
Small sample, short duration, high dropout from gastrointestinal effects.
Supplements Studied
Modest reductions in fasting glucose occurred only at the higher vanadyl sulfate dose, with dose-limiting gastrointestinal effects.
Outcomes Measured
Only the higher dose produced modest reductions in fasting glucose and HbA1c; insulin sensitivity improvements were inconsistent and gastrointestinal effects were dose limiting.
Only the higher vanadyl sulfate dose produced modest reductions in fasting glucose and HbA1c.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.